Fig. 3

Use of combination therapy with a central antitussive at index month and at Month 12. ICS: inhaled corticosteroids; LABA: long-acting beta-adrenergic receptor antagonists. Antimicrobials refer to respiratory quinolones and 14- and 15-member ring macrolides only. Black box: Index month; White box: Month 12. The total number of participants with a prescription claim for a medication of interest at Month 12 was 1,317 in Population ‘All’, 628 in Population 1, 689 in Population 2, 394 in the ‘other coughs’ subgroup, 281 in the cough-variant asthma subgroup and 32 in the atopic/allergic cough group. The proportion of medication use in combination is calculated as the number of participants using a given medication class in combination with a central antitussive divided by the total number of users of the given class. The percentages to the right of each pair of bars represent the change (%) in the proportion of medication use in combination between the index month and Month 12. The asterisk indicates the medication classes which were used in combination with corticosteroids in less than 10 patients at either time point